Please assess the completion status of the following clinical trial:

Trial Title: Autologous Platelet Rich Plasma (PRP) for the Treatment of Chronic Non-Healing Ulcers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female 18 to 85 years of age~* Chronic or Non-healing ulcer of any etiology (venous, pressure, arterial or diabetic foot ulcer) which is at least 4 weeks old~* Index foot ulcer located on the plantar, medial or lateral aspect of the foot (including all toe surfaces)~* Wound area (length x width) measurement must be between 0.5 cm\^2 and 10 cm\^2, inclusive~* If more than one non-healing ulcers is present, the largest wound will be selected~* Index ulcer must be clinically non-infected~* Full-thickness ulcer without exposure of bone, muscle, ligament or tendon~* Written informed consent must be obtained from either the patient or the patients legally acceptable representative prior to enrollment~Exclusion Criteria:~* Patients with known sensitivity to components of the PRP kit (calcium chloride, thrombin, acid citrate dextrose solution A (ACD-A))~* Smokers and individuals with systemic disease or history of anticoagulant, immuno-suppressive or antibiotic therapy in the last 3 months~* Platelet count \< 105 x 10\^3/ uL (according to CBC)~* Hemoglobin level \< 10 g/dL (according to CBC)~* Wound is clinically infected~* Presence of platelet dysfunction syndrome or critical thrombocytopenia~* Bleeding disorders, collagen vascular disease or severe cardiovascular disorder~* Any malignancy other than non-melanoma skin cancer~* Patient is currently receiving or has received radiation or chemotherapy within 3 months prior to treatment~* If female, patient is pregnant, nursing or plans to become pregnant during the duration of the study~* Subject has inadequate venous access for blood draw required for PRP preparation~* Any chronic condition requiring the use of systemic corticosteroids 30 days prior to study entry and anytime during the course of the study~* Subject is on dialysis or has uncontrolled sugar levels

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Autologous PRP Gel and PRP Injection (Type: EXPERIMENTAL): Autologous PRP will be prepared using an advanced rapid point-of-care technology, the Res-Q™ 60 PRP system at the patient's bed side. The Activator solution for PRP gel will be prepared by combining human thrombin (500 IU/ml) with 1% Calcium Chloride.

Based on this trial design, predict the completion outcome and termination type (if applicable).